Evidence map›Paper›PMID 38538635›Full record

ArticleScientific reports2024

Modified streptavidin-biotin based lateral flow test strip for rapid detection of SARS-CoV-2 S1 antigen in saliva samples.

Manal Kamel, Shimaa Atta, Sara Maher, Hesham Abd Elaziz, Zeinab Demerdash

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Manal KamelImmunology Department, Theodor Bilharz Research Institute, Giza, Egypt.
Shimaa AttaImmunology Department, Theodor Bilharz Research Institute, Giza, Egypt. attashimaa@yahoo.com.
Sara MaherImmunology Department, Theodor Bilharz Research Institute, Giza, Egypt.
Hesham Abd ElazizSurgery Department, Theodor Bilharz Research Institute, Giza, Egypt.
Zeinab DemerdashImmunology Department, Theodor Bilharz Research Institute, Giza, Egypt.
Theodor Bilharz Research Institute · EG

Funding

Science, Technology & Innovation Funding Authority (STDF) 77741
6 · The paper itself

Abstract

Compared to other infectious diseases, for which LFT development can take years, SARS-CoV-2 antigen LFTS were developed and deployed within months. LFTS for antigen detection were adopted on an unprecedented scale during the COVID-19 pandemic, but many of them lack the sensitivity especially for samples with low viral load. In our previous work, we developed an enhanced signal strip for detection of SARS CoV-2 SI antigens in saliva. Here we introduce some modification to improve the sensitivity, and specificity, and to lower the cost of the strip, by using biotin streptavidin (BS) system. In the modified BS strip, gold-streptavidin and biotinylated Nanobodies (Nbs) against S1 antigen were externally mixed with the tested samples (saliva or nasopharyngeal swab) before their application on the sample pad of the test strip containing angiotensin converting enzyme (ACE-2), as the capturing probe. The study included 320 individuals, with 180 being positively confirmed by RT-PCR and 140 confirmed negative, as well as, 45 health care workers, who were responsible for screening and handling of surgical cases in General Surgery Department and COVID clinic of TBRI. Our results proved that modified BS strip improved the overall sensitivity and specificity of S1antigen detection in saliva samples (95.21% and 99.29% respectively) compared to our previously developed enhanced LFTS (91.66% and 98.57% respectively). Also, the sensitivity of cases with Ct ≤ 30, Ct

Indexed as

BiotinCOVID-19Neoplasm ProteinsAntigens, ViralHumansNasopharynxPandemicsSalivaSARS-CoV-2Specimen HandlingStreptavidinAntigens, ViralBiotinNeoplasm Proteinssarcoma-associated antigen S1StreptavidinBiotinNanobodiesRapid testSalivaSARS-CoV-2 S1Streptavidin

Identifiers

PMID38538635
PMCPMC10973412
OpenAlexW4393234775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.